Last updated: September 8, 2026
Idelvion, the brand name for albutrepenonacog alfa, is a recombinant coagulation factor IX linked to recombinant albumin. CSL Behring markets the product for hemophilia B. Its commercial value comes from extended half-life, reduced infusion frequency, and a differentiated delivery profile rather than from broad market expansion.
Idelvion faces competition from standard half-life factor IX products, other extended-half-life products, and gene therapy. Its principal commercial risks are high treatment cost, payer pressure, competing factor IX products, and the emergence of one-time gene therapies such as Hemgenix. Its regulatory exclusivity has expired, but patent and manufacturing protections can extend commercial protection beyond the first FDA approval date.
What is Idelvion and how does the albumin fusion work?
Idelvion is a recombinant factor IX-albumin fusion protein. The factor IX component restores the coagulation pathway, while the albumin component increases circulation time by using albumin's naturally long plasma half-life.
The FDA approved Idelvion on March 4, 2016, for adults and children with hemophilia B for:
- On-demand control and prevention of bleeding
- Perioperative management
- Routine prophylaxis to reduce bleeding frequency
The product is manufactured in a recombinant mammalian-cell system and does not rely on human plasma donations. The FDA label identifies the active ingredient as coagulation factor IX, recombinant, albumin fusion protein. [1]
| Attribute |
Idelvion |
| Active ingredient |
Albutrepenonacog alfa |
| Drug class |
Recombinant factor IX replacement |
| Fusion partner |
Recombinant albumin |
| Manufacturer |
CSL Behring |
| FDA approval |
March 4, 2016 |
| Primary indication |
Hemophilia B |
| Administration |
Intravenous infusion |
| Product type |
Biologic |
| U.S. regulatory pathway |
Biologics license application |
| Standard generic pathway |
Not an ANDA product |
| Biosimilar status |
No approved biosimilar identified through June 2024 |
Idelvion's terminal half-life is approximately four to five times longer than that of standard half-life factor IX products, although the exact value varies by patient age and pharmacokinetic characteristics. The FDA label reports a mean half-life of roughly 100 hours in adults and lower values in pediatric patients. [1]
What dosing advantage does Idelvion provide?
Idelvion's commercial proposition is fewer infusions for prophylaxis. The FDA label recommends individualized dosing, but routine prophylaxis generally uses weekly administration in adults and more frequent dosing in children.
| Use |
Typical labeled approach |
| Routine prophylaxis in adults |
25 to 40 IU/kg every 7 days |
| Routine prophylaxis in children |
40 to 55 IU/kg every 7 days |
| Minor bleeding |
Dose calculated from required factor IX recovery |
| Major bleeding |
Higher or repeated dosing based on clinical response |
| Surgery |
Individualized perioperative dosing and monitoring |
The product does not eliminate intravenous administration. That limits convenience relative to gene therapy, but it remains relevant for patients who are not eligible for gene therapy, do not achieve adequate gene-therapy expression, or prefer replaceable factor treatment.
How does Idelvion compare with competing factor IX drugs?
Idelvion competes in the extended-half-life factor IX segment. Its primary branded competitors are Alprolix, Rebinyn, and Refixia in markets where the latter is available. Benefix remains a major standard-half-life comparator.
| Product |
Active ingredient |
Half-life strategy |
Manufacturer |
Commercial positioning |
| Idelvion |
Albutrepenonacog alfa |
Albumin fusion |
CSL Behring |
Long-acting prophylaxis |
| Alprolix |
Eftrenonacog alfa |
Fc fusion |
Sanofi |
Long-acting prophylaxis |
| Rebinyn |
Nonacog beta pegol |
PEGylation |
Novo Nordisk |
Extended half-life |
| Benefix |
Nonacog alfa |
Standard half-life |
Pfizer |
Established factor IX replacement |
| Hemgenix |
Etranacogene dezaparvovec |
AAV gene therapy |
CSL Behring |
One-time gene therapy |
The most direct product comparison is Idelvion versus Alprolix. Both are extended-half-life recombinant factor IX products, but they use different molecular designs. Idelvion uses albumin fusion, while Alprolix uses Fc fusion. Product selection depends on pharmacokinetics, bleed control, infusion preferences, inhibitor history, payer access, and physician experience.
Hemgenix changes the market structure more significantly than another factor replacement product. CSL Behring markets both Hemgenix and Idelvion, allowing the company to cover a one-time gene-therapy option and a chronic replacement option. The products can be commercially complementary, although successful gene-therapy uptake reduces the long-term number of factor IX prophylaxis patients.
What is the FDA exclusivity status of Idelvion?
Idelvion is a biologic and is not subject to the same Orange Book listing system used for small-molecule drugs. Its regulatory information is tracked through the FDA's Purple Book and the product's biologics license.
The FDA approval date was March 4, 2016. The 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act therefore ran to March 2028, subject to statutory treatment of pediatric and other exclusivity extensions. No approved U.S. biosimilar to Idelvion was identified through June 2024. [2]
The product's orphan-drug exclusivity period was shorter than the BPCIA reference-product period. Orphan exclusivity generally lasts seven years from approval, placing the principal period around 2023. Orphan exclusivity does not block all competing products in every circumstance, particularly where a competitor can establish clinical superiority or pursue a legally distinct indication.
Does Idelvion have an Orange Book listing?
No. Idelvion is a biologic, so an Orange Book entry should not be expected. The Orange Book is principally used for approved drug products regulated through abbreviated new drug applications. Idelvion is regulated under a biologics license application.
Patent information for a biologic must be evaluated through the patent owner's public disclosures, USPTO records, FDA biologics information, licensing documents, and litigation records. The absence of an Orange Book entry does not indicate the absence of patent protection.
What patents protect Idelvion?
Idelvion's protection is expected to involve several layers:
- Factor IX-albumin fusion constructs
- Nucleic acid sequences and expression vectors
- Host-cell production systems
- Purification and manufacturing processes
- Pharmaceutical compositions
- Dosing and prophylaxis methods
- Treatment methods for hemophilia B
The relevant patent estate is more complex than a single active-ingredient patent. The core fusion-protein claims typically have the greatest commercial importance, while process and formulation claims can create additional barriers to biosimilar development.
Public product information does not provide a single definitive patent-expiration date for all Idelvion-related claims. Patent terms can differ by jurisdiction, priority date, terminal disclaimers, patent-term adjustment, patent-term extension, and claim scope. A commercial entry analysis therefore requires a claim-by-claim review of CSL-related patent families rather than reliance on the 2016 FDA approval date.
| Protection layer |
Likely business effect |
| Fusion-protein composition claims |
Can block direct copies of the albumin-factor IX molecule |
| DNA and vector claims |
Can restrict specific recombinant production designs |
| Cell-line and process claims |
Increase manufacturing complexity |
| Formulation claims |
May limit certain liquid or storage presentations |
| Method-of-use claims |
Can affect prophylaxis and treatment indications |
| Manufacturing know-how |
May remain valuable after patent expiry |
How strong is the Idelvion patent estate?
The estate is commercially meaningful because a competitor must reproduce a complex recombinant fusion biologic, demonstrate comparability, and obtain regulatory approval. Patent strength depends on the validity and enforceability of specific claims, not on the number of patent families alone.
Composition claims covering the exact albumin-factor IX architecture are generally more important than narrow dosing claims. Manufacturing claims can also create practical barriers, but their value depends on whether a biosimilar developer can design around them without compromising product quality or regulatory comparability.
Are there Paragraph IV challenges to Idelvion?
Traditional Paragraph IV litigation does not apply to Idelvion because Paragraph IV certifications arise under the Hatch-Waxman framework for abbreviated new drug applications. A biosimilar applicant would use the BPCIA patent-dispute process rather than file an ANDA with a Paragraph IV certification.
No publicly identified Idelvion biosimilar litigation or BPCIA patent dispute had materially affected the U.S. product through June 2024. This position can change if a biosimilar sponsor files a product application and initiates the statutory patent-information exchange.
What generic entry risks exist for Idelvion?
A conventional generic launch is unlikely because Idelvion is a recombinant biologic. The relevant risk is biosimilar or interchangeable-biosimilar entry.
The main entry scenarios are:
| Scenario |
Timing pressure |
Commercial impact |
| No biosimilar filing |
Low near-term pressure |
CSL retains broad pricing control |
| Biosimilar after March 2028 |
Moderate |
Initial price erosion and contracting pressure |
| Multiple biosimilars |
High |
Greater discounts and hospital or payer substitution |
| Gene-therapy expansion |
Structural |
Decline in treated factor demand |
| Patent settlement |
Variable |
Entry date depends on negotiated terms |
Biosimilar development is difficult because the product requires recombinant protein production, analytical comparability, pharmacokinetic assessment, immunogenicity monitoring, and clinical evidence. Factor IX products also require reliable control of potency and thrombogenicity.
What is Idelvion's financial trajectory?
CSL Behring does not generally report Idelvion revenue as a separate public line item in its annual financial statements. CSL reports product groups and business segments, which limits precise product-level revenue reconstruction.
The financial trajectory has four phases:
Launch and adoption: 2016 to 2019
Idelvion entered a market already served by established factor IX products. Adoption depended on conversion from standard-half-life products and competition with Alprolix and Rebinyn. Its extended dosing interval supported premium pricing, but payer controls and specialist prescribing slowed rapid substitution.
Expansion and portfolio maturity: 2020 to 2022
The product benefited from the established demand for prophylactic factor replacement. Home infusion and patient convenience remained important drivers. The COVID-19 period introduced treatment-access and supply-chain pressure but did not remove the underlying need for hemophilia B replacement therapy.
Gene-therapy transition: 2022 onward
The FDA approved Hemgenix in November 2022. Hemgenix is a one-time treatment for adults with hemophilia B who use factor IX prophylaxis, have current or historical life-threatening hemorrhage, or have repeated serious spontaneous bleeding and lack neutralizing antibodies to the AAV5 vector. [3]
For CSL, Hemgenix creates both an internal substitution risk and a portfolio opportunity. The company can capture value from patients moving to gene therapy, but successful uptake may reduce lifetime factor consumption in treated patients.
Long-term maturity: 2028 and after
The end of the BPCIA reference-product exclusivity period in 2028 increases the probability of biosimilar competition. Actual entry will depend on patent outcomes, development economics, regulatory filings, manufacturing capacity, and payer adoption.
How significant is Idelvion to CSL Behring revenue?
Idelvion is strategically important but is not disclosed as a standalone revenue driver in CSL's public reporting. CSL Behring's broader revenue base includes immunoglobulins, albumin, specialty products, recombinant therapies, and other plasma-derived products. Idelvion is therefore unlikely to determine CSL's consolidated financial performance by itself.
Its financial importance is better assessed through:
- Market share in hemophilia B
- Net price after rebates
- Annual factor consumption per patient
- Prophylaxis persistence
- Switching from standard-half-life products
- Biosimilar timing
- Hemgenix conversion rates
- Manufacturing cost and capacity
A gene-therapy conversion can reduce recurring Idelvion revenue per patient, but the loss is not necessarily immediate across the total hemophilia B population. Patient eligibility, vector immunity, clinical durability, reimbursement, and physician adoption constrain the speed of substitution.
What licensing deals affect Idelvion?
No major external licensing transaction is required to explain Idelvion's current commercial ownership. CSL Behring is the marketed-product sponsor and controls the commercial franchise.
The product is part of CSL's broader recombinant and specialty-hemostasis strategy. The most commercially important portfolio relationship is the coexistence of Idelvion with Hemgenix. This gives CSL exposure to both chronic replacement therapy and one-time gene therapy in hemophilia B.
What litigation affects Idelvion?
No major publicly identified U.S. patent litigation involving Idelvion had materially disrupted its commercial status through June 2024. The absence of a reported case does not remove future litigation risk. The most likely dispute would involve a biosimilar sponsor, patent validity, claim construction, or manufacturing design-around issues.
Potential litigation would likely address:
- Whether a biosimilar infringes fusion-protein claims
- Validity of composition or process patents
- Patent-term calculations
- BPCIA patent-dispute procedures
- Launch timing and settlement terms
- Injunctive relief or damages
What geographic markets are most important for Idelvion?
Idelvion is marketed in the United States and major international markets, including Europe. Regulatory status, reimbursement, and competitive intensity vary by jurisdiction.
The United States is the most important market for premium factor pricing and specialty pharmacy distribution. Europe has substantial demand but more centralized pricing controls and national reimbursement negotiations. Other markets may be constrained by diagnosis rates, treatment access, local tenders, and factor availability.
The product's manufacturing and distribution network must maintain cold-chain integrity and supply continuity. Recombinant production reduces dependence on plasma collection but does not remove the need for specialized cell culture, purification, quality testing, and sterile fill-finish capacity.
What is the likely generic or biosimilar launch scenario?
The most credible U.S. launch window begins after March 2028, when the 12-year reference-product exclusivity period has run. Patent claims could move the practical launch date later.
A first biosimilar would likely target patients whose payers prioritize lower net cost and who can be switched without disrupting bleed control. Initial erosion may be limited because hemophilia treatment is specialist-managed and patients often remain on a stable product. Deeper erosion would require multiple approved products, payer-driven substitution, and physician confidence in interchangeability.
Key Takeaways
- Idelvion is albutrepenonacog alfa, a recombinant factor IX fused to albumin.
- CSL Behring received FDA approval on March 4, 2016.
- The product's principal advantage is an extended half-life that supports less frequent prophylaxis.
- Idelvion competes with Alprolix, Rebinyn, Benefix, and Hemgenix.
- Idelvion has no Orange Book listing because it is a biologic regulated under a biologics license.
- The 12-year BPCIA reference-product exclusivity period runs to approximately March 2028.
- No approved U.S. biosimilar or material Idelvion patent litigation was identified through June 2024.
- CSL does not publicly disclose Idelvion revenue as a standalone financial line.
- Hemgenix creates the largest long-term structural risk to recurring factor IX demand.
- Patent protection is likely layered across composition, sequence, manufacturing, formulation, and method-of-use claims.
FAQs
Is Idelvion the same as factor IX?
No. Idelvion is a specific recombinant factor IX product. Its full active ingredient is albutrepenonacog alfa, a factor IX molecule fused to recombinant albumin.
Can Idelvion be replaced by Hemgenix?
Some eligible adults may transition to Hemgenix, but the products are not interchangeable in all patients. Hemgenix requires eligibility for gene therapy and does not remove the need for factor IX treatment in every patient.
Is Idelvion plasma-derived?
No. Idelvion is produced through recombinant technology. It is not manufactured from pooled human plasma.
Does Idelvion have an interchangeable biosimilar?
No interchangeable biosimilar to Idelvion had been approved in the United States through June 2024.
What will determine Idelvion's post-2028 value?
The main variables are biosimilar entry, patent enforcement, net pricing, Hemgenix adoption, gene-therapy durability, patient switching behavior, and CSL's ability to retain hemophilia B patients within its broader treatment portfolio.
References
-
U.S. Food and Drug Administration. (2023). Idelvion prescribing information. CSL Behring LLC.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2022). Hemgenix prescribing information. CSL Behring LLC.
-
CSL Limited. (2023). Annual report 2023. CSL Limited.
-
U.S. Congress. (2010). Patient Protection and Affordable Care Act, Title VII, Biologics Price Competition and Innovation Act of 2009. 42 U.S.C. ยง 262.
